Human Gene Set: WORSCHECH_TUMOR_EVASION_AND_TOLEROGENICITY_UP

For the Mouse gene set with the same name, see WORSCHECH_TUMOR_EVASION_AND_TOLEROGENICITY_UP

Standard name WORSCHECH_TUMOR_EVASION_AND_TOLEROGENICITY_UP
Systematic name M1989
Brief description Selected genes with immunologic function which were reciprocally changed in evasion and tolerogenic tumor models.
Full description or abstract We have previously shown T-cell-mediated rejection of the neu-overexpressing mammary carcinoma cells (MMC) in wild-type FVB mice. However, following rejection of primary tumors, a fraction of animals experienced a recurrence of a neu antigen-negative variant (ANV) of MMC (tumor evasion model) after a long latency period. In the present study, we determined that T cells derived from wild-type FVB mice can specifically recognize MMC by secreting IFN-gamma and can induce apoptosis of MMC in vitro. Neu transgenic (FVBN202) mice develop spontaneous tumors and cannot reject it (tumor tolerance model). To dissect the mechanisms associated with rejection or tolerance of MMC tumors, we compared transcriptional patterns within the tumor microenvironment of MMC undergoing rejection with those that resisted it either because of tumor evasion/antigen loss recurrence (ANV tumors) or because of intrinsic tolerance mechanisms displayed by the transgenic mice. Gene profiling confirmed that immune rejection is primarily mediated through activation of IFN-stimulated genes and T-cell effector mechanisms. The tumor evasion model showed combined activation of Th1 and Th2 with a deviation toward Th2 and humoral immune responses that failed to achieve rejection likely because of lack of target antigen. Interestingly, the tumor tolerance model instead displayed immune suppression pathways through activation of regulatory mechanisms that included in particular the overexpression of interleukin-10 (IL-10), IL-10 receptor, and suppressor of cytokine signaling (SOCS)-1 and SOCS-3. These data provide a road map for the identification of novel biomarkers of immune responsiveness in clinical trials.
Collection C2: Curated
      CGP: Chemical and Genetic Perturbations
Source publication Pubmed 18381452   Authors: Worschech A,Kmieciak M,Knutson KL,Bear HD,Szalay AA,Wang E,Marincola FM,Manjili MH
Exact source Evasion > 1 & Tolerogenic < 1
Related gene sets (show 3 additional gene sets from the source publication)

(show 41 gene sets from the same authors)
External links
Filtered by similarity ?
Source species Mus musculus
Contributed by Arthur Liberzon (MSigDB Team)
Source platform or
identifier namespace
MOUSE_GENE_SYMBOL
Dataset references  
Download gene set format: grp | gmt | xml | json | TSV metadata
Compute overlaps ? (show collections to investigate for overlap with this gene set)
Compendia expression profiles ? GTEx compendium
Human tissue compendium (Novartis)
Global Cancer Map (Broad Institute)
NCI-60 cell lines (National Cancer Institute)
Advanced query Further investigate these 31 genes
Gene families ? Categorize these 31 genes by gene family
Show members (show 33 source identifiers mapped to 31 genes)
Version history 3.1: First introduced

We need your help: Update on GSEA/MSigDB funding support

Last November we submitted a proposal to NCI's Information Technology for Cancer Research (ITCR) program for the continued funding of GSEA and MSigDB. Unfortunately, our proposal was not funded in this round, but we were encouraged to resubmit for the next one. This funding is critical for our continuing support and enhancement of the GSEA-MSigDB resource.

For our original submission many of you sent us emails of support, an important requirement for these grants. We now ask for your help again. We would greatly appreciate a short email message from you describing how the resource has been of value to your work and any concerns you may have about its continued availability.

Please send us your message of support to gsea-los@broadinstitute.org on or before Monday June 5, 2023.

Thanks in advance for your help and support.
The GSEA/MSigDB Team.


See MSigDB license terms here. Please note that certain gene sets have special access terms.